Pharmaceutical Intermediates Market Key Players and Forecast by 2028
Pharmaceutical Intermediates Market Forecast to 2028 - Analysis By Type (GMP, and Non GMP); Applications (Antibiotics, Antipyretic Analgesics, Vitamins, and Others); Distribution Channel (Distributor, and Direct Sales), and Geography
- Status : Published
- Report Code : TIPRE00005559
- Category : Life Sciences
- No. of Pages : 185
- Available Report Formats :
- Last update date : June 17, 2024
2020 Market Size
US$ 27.36 Bn
Base year value
2028 Forecast
US$ 37.29 Bn
Projected by 2028
CAGR 2021-2028
4.2 %
Growth rate
Addressable Market
US$ 264.57 Bn
(2021-2028)
The pharmaceutical intermediates market is expected to reach US$ 37,290.33 million in 2028 from US$ 27,356.70 million in 2020. The market is estimated to grow with a CAGR of 4.2% from 2021-2028.
The pharmaceutical intermediates market has been analyzed on the basis of type, application, distribution channel, and region. The market based on region is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. The report emphasizes on parameters such as market trends, technological advancements, market dynamics, and leading company’s competitive landscape analysis to offers insights and in-depth analysis of the pharmaceutical intermediates market. It also includes the analysis of COVID-19 pandemic across the market in all the key regions.
Market Research Highlights
- North America dominated the market with 39.4% share in 2020.
- Asia Pacific is poised to grow at a CAGR of 4.9% over the forecast period.
- United States market is projected to grow at a CAGR of 4.6% over the forecast period.
- By Type, the GMP segment accounted for the largest market share of 73.2% in 2020.
- By Application, the Vitamins segment is anticipated to witness the fastest growth, registering a CAGR of 6.7% over the forecast period
- By Distribution Channel, the Direct Sales segment accounted for the largest market share of 62% in 2020.
- The report profiles key industry players such as Pfizer Inc, BASF SE, Sanofi SA, chiracon GmbH, Midas Pharma GmbH, Codexis Inc, Lianhe Chemical Technology Co., Ltd., Dishman Carbogen Amcis Ltd, Dextra Laboratories Limited, Vertellus Holdings LLC, while also analyzing key developments in novel ideas, disruptive products, and innovative services that could reshape the future market and reveal emerging themes across the industry.
Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.
● REPORT CUSTOMIZATION
Tailor This Report To Align With Your Specific Business Requirements
This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.
Customize This Report →WHAT YOU CAN ADJUST
- ● Segmentations
- ● Geography
- ● Competitive Analysis
- ● Language Preferences
Pharmaceutical Intermediates Market: Strategic Insights
-
Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Market Insights
Rising Prevalence of Chronic Diseases and Infectious Diseases
Pharmaceutical intermediates are the building blocks of active pharmaceutical ingredients (APIs). These are raw materials that undergo molecular change or processing during bulk drug production. Thus, the requirement of pharmaceutical intermediates increases with the rise in demand for drugs to treat chronic diseases. As per the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the US suffer from at least one chronic disease such as cancer, heart disease, lung disease, stroke, neurological disease, diabetes, and kidney diseases. Moreover, 4 in 10 adults in the country have two or more chronic diseases. Additionally, according to the press release by the European Chronic Disease Alliance (ECDA), in 2014, 9 out of 10 people in Europe die due to chronic diseases. Thus, 70–80% of the total healthcare costs are spent on the management of chronic diseases.
The surging prevalence of infectious diseases, especially in Southeast Asia, is also likely to propel the demand for APIs in the coming years, eventually driving the growth of the pharmaceutical intermediate market. For instance, as per the Revised National Tuberculosis Control Programme Report, around 4.4 lakh patients died due to tuberculosis in India in 2018, that is 29% of the total 1.5 million deaths caused by the disease across the world. Thus, such high prevalence of chronic diseases and infectious diseases is bolstering the demand for drugs, eventually highlighting the need of pharmaceutical intermediates.
Type-Based Insights
The pharmaceutical intermediates market, by type, is segmented into GMP, and non GMP. The GMP segment held the largest share of the market in 2020, whereas the same segment is anticipated to register the highest CAGR of 4.4% in the market during the forecast period.
Application-Based Insights
The pharmaceutical intermediates market, by application, is segmented antibiotics, antipyretic analgesics, vitamins, and others. The antibiotics segment held the largest share of the market in 2020, also, this segment is anticipated to register the highest CAGR of 4.9% in the market during the forecast period.
Distribution Channel-Based Insights
On the basis of distribution channel, the pharmaceutical intermediates market has been segmented into distributor, and direct sales. The direct sales segment held the largest share of the market in 2020, and distributor segment is estimated to register the highest CAGR of 4.2% in the market during the forecast period.
Companies operating in the pharmaceutical intermediates market are adopting organic strategies such as product launches and expansions to expand their footprint and product portfolio worldwide as well as to address the growing demands.
Pharmaceutical Intermediates Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2020 | US$ 27.36 Billion |
| Market Size by 2028 | US$ 37.29 Billion |
| Global CAGR (2020 - 2028) | 4.2% |
| Historical Data | 2018-2019 |
| Forecast period | 2021-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
Pharmaceutical Intermediates Market Players Density: Understanding Its Impact on Business Dynamics
The Pharmaceutical Intermediates Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
By Type
- GMP
- Non-GMP
By Application
- Antibiotics
- Antipyretic Analgesics
- Vitamins
- Others
By Distribution Channel
- Distributor
- Direct Sales
By Geography
-
North America
- US
- Canada
- Mexico
-
Europe
- Germany
- France
- Italy
- United Kingdom
- Spain
- Switzerland
- Belgium
- Greece
- Norway
- Portugal
- Sweden
- Czech Republic
- Croatia
- Ireland
- Denmark
- Netherland
- Russia
- Rest of Europe
-
Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
-
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Turkey
- Rest of MEA
-
South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Company Profiles
- Pfizer, Inc
- Dishman Group
- Dextra Laboratories Limited
- Sanofi Winthrop Industries S.A.
- Vertellus Holdings LLC
- BASF SE
- Lianhetech
- Codexis
- Midas Pharma GmbH
- Chiracon GmbH
Frequently Asked Questions
- Comprehensive Market Sizing and Forecast Analysis
- Detailed Segmentation Analysis
- In-Depth Market Dynamics Assessment
- Regional and Country-Level Insights
- Competitive Landscape and Company Benchmarking
- Strategic Business Intelligence
Recent Reports
Testimonials
The Insight Partners provided valuable market intelligence that supported our global go-to-market strategy. Their team was professional, responsive, and attentive to our feedback, providing thoughtful analysis and helpful methodological clarifications throughout the project.
Junmo Kim Chief Financial Officer (CFO), Enertech Co., Ltd.
The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.
RAN KEDEM Partner, Reali Technologies LTDs
I requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.
JEAN-HERVE JENN Chairman, Future Analytica
We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.
PIYUSH NAGPAL Sr. Vice President, High Beam Global
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
YUKIHIKO ADACHI CEO, Deep Blue, LLC.
This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.
JOHN SUZUKI President and Chief Executive Officer, Board Director, BK Technologies
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Get Free Sample for